|
1
|
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.
|
Am J Trop Med Hyg
|
2014
|
1.51
|
|
2
|
Heterogeneous decrease in malaria prevalence in children over a six-year period in south-western Uganda.
|
Malar J
|
2011
|
1.35
|
|
3
|
Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia.
|
Malar J
|
2013
|
1.15
|
|
4
|
Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence.
|
J Virol
|
2002
|
1.01
|
|
5
|
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data.
|
BMC Med
|
2015
|
0.99
|
|
6
|
Vaccinia virus-induced microtubule-dependent cellular rearrangements.
|
Traffic
|
2006
|
0.97
|
|
7
|
Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia.
|
Trop Med Int Health
|
2010
|
0.95
|
|
8
|
Risk factors and mortality associated with resistance to first-line antiretroviral therapy: multicentric cross-sectional and longitudinal analyses.
|
J Acquir Immune Defic Syndr
|
2015
|
0.76
|
|
9
|
Meeting report: EMBO workshop 'Cell Biology of Virus Infection', September 25-29, 2004, EMBL, Heidelberg, Germany.
|
Traffic
|
2005
|
0.75
|